**GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma**

Yeqing Dong, Yongsheng Huang, Chengyan Fan, Liang Wang, Ran Zhang, Wenhua Li, Zhengguang Guo, Dong Wang and Zhi Zheng

**Abstract**

Pheochromocytoma/paraganglioma (PPGL) is an endocrine tumor of the chromaffin cells in the adrenal medulla or the paraganglia. Currently, about 70% of PPGLs can be explained by germline or somatic mutations in several broadly expressed susceptibility genes including RET, VHL, and SDHB, while for the remaining, mainly sporadic cases, the pathogenesis is still unclear. Even for known susceptible genes, how mutations in these mostly ubiquitous genes result in tissue-specific pathogenesis remains unanswered, and why RET-mutated tumors almost always occur in the adrenal while SDHB-mutated tumors mostly occur extra-adrenal remains a mystery. By analyzing 22 sporadic PPGLs using SNP 6.0 genotyping arrays combined with expression profiling of 4 normal and 4 tumor tissues, we identified GIPC2, a gene located at 1p31.1 with preferential expression in adrenal and inducible by adrenal glucocorticoid, as a novel putative tumor suppressor gene for PPGLs. Copy number deletion and GIPC2 promoter hypermethylation but not GIPC2 mutation, accompanied with reduced GIPC2 expression, were observed in 39 of 55 PPGLs in our cohort. Examination of a published expression database consisting of 188 PPGLs found little GIPC2 expression in Cluster 1A (SDHx-associated) and Cluster 2A (NF1/RET-associated) tumors, but less pronounced reduction of GIPC2 expression in Cluster 1B (VHL-associated) and Cluster 2B/2C tumors. GIPC2 induced p27, suppressed MAPK/ERK and HIF-1α pathways as well as cancer cell proliferation. Overexpressing GIPC2 in PC12 cells inhibited tumor growth in nude mice. We found GIPC2 interacted with the nucleoprotein NONO and both proteins regulated p27 transcription through the same GGCC box on p27 promoter. Significantly, low expression of both GIPC2 and p27 was associated with shorter disease-free survival time of PPGLs patients in the TCGA database. We found that PPGL-causing mutations in RET and in SDHB could lead to primary rat adrenal chromaffin cell proliferation, ERK activation, and p27 downregulation, all requiring downregulating GIPC2. Notably, the RET-mutant effect required the presence of dexamethasone while the SDHB-mutant effect required its absence, providing a plausible explanation for the tumor location preference. In contrast, the PPGL-predisposing VHL mutations had no effect on proliferation and GIPC2 expression but caused p53 downregulation and reduced apoptosis in chromaffin cells compared with wild-type VHL. Thus, our study raises the importance of cortical hormone in PPGL development, and GIPC2 as a novel tumor suppressor provides a unified molecular mechanism for the tumorigenesis of both sporadic and hereditary tumors of Clusters 1A and 2A concerning SDHB and RET, but not tumors of Cluster 1B concerning VHL and other clusters.

**Introduction**

Pheochromocytomas and paragangliomas (PPGLs) are catecholamine-secreting tumors that arise from chromaffin cells of the adrenal medulla and paraganglia,
respectively. They can occur sporadically or as a part of different hereditary tumor syndromes, such as multiple endocrine neoplasia type 2 (MEN2) syndrome and Von Hippel-Lindau disease syndrome\(^1\)\(^–\)\(^3\). The germline and somatic mutations of about 20 genes can account for the pathogenesis of up to 70% of PPGLs\(^4\)\(^–\)\(^10\). The application of next-generation sequencing accelerated the discovery of driver susceptibility gene mutations. However, newly discovered mutations tend to occur in decreasing frequencies in PPGLs, suggesting that key driver mutations are close to being all found. Still, the remaining 30%, mostly sporadic cases do not harbor any known somatic mutations, indicating non-mutation-based mechanisms may be of importance for these cases.

Even for hereditary cases, the molecular mechanism of PPGL is far from clear. Few studies addressed how susceptibility gene mutations lead to PPGL pathogenesis in chromaffin cells. This is likely due to the lack of proper cellular models that can capture the phenotypes. For example, when PPGL-predisposing RET C634R mutation was introduced to PC12 rat pheochromocytoma cells, the cells underwent neuronal differentiation rather than proliferation\(^11\). On the other hand, for MEN 2A syndrome patients with the common RET C634R mutation, only about 50% develop pheochromocytoma\(^12\), suggesting the tumorigenesis may require additional genetic events\(^13\). Whole-genome scanning of PPGLs by array CGH (Comparative Genomic Hybridization) revealed that hereditary and sporadic PPGLs often harbor high-frequency deletions on chromosomes 1p and 3q (Supplementary Fig. 1). By analyzing 4 tumors and 4 normal adrenal medulla tissues on U133 plus 2.0 arrays, we identified 5507 genes with copy number deletion and increased expression significantly in tumors. A total of 25 genes were found to have both copy number deletion and decreased expression (Supplementary Table 1). One of these genes, GIPC2, which is located at human chromosome 1p31.1\(^2\)\(^–\)\(^4\), was scored as preferentially expressed in human adrenal by the Tissue-Specific Genes Database (TISGED) analysis (http://bioinf.xmu.edu.cn:8080/databases/TISGeD/index.html), and was selected for further study.

We used SNP 6.0 arrays to analyze 22 sporadic PPGL tumors without common predisposing germline alterations and 14 matched blood samples, from a cohort of 55 PPGLs including 49 pheochromocytomas and 6 paraganglia (Supplementary File 1). In the analysis of copy number alterations, we noted significant copy number deletions on chromosomes 1p and 3q (Supplementary Fig. 1A), and identified 5507 genes with copy number deletion after narrowing down the minimal overlapping deletion intervals in 1p and in 3q. By analyzing 4 tumors and 4 normal adrenal medulla tissues on U133 plus 2.0 arrays, we identified 260 genes that were downregulated significantly in tumors. A total of 25 genes were found to have both copy number deletion and decreased expression (Supplementary Table 1). One of these genes, GIPC2, which is located at human chromosome 1p31.1\(^2\)\(^–\)\(^4\), was scored as preferentially expressed in human adrenal by the Tissue-Specific Genes Database (TISGED) analysis (http://bioinf.xmu.edu.cn:8080/databases/TISGeD/index.html), and was selected for further study.

We found 15 out of 22 samples had copy number deletion of GIPC2 from SNP arrays data (an example in Supplementary Fig. 1B), and 39 tumors had copy number deletion from our cohort of 55 PPGL samples by qPCR, including all 7 RET-mutated PPGL (Fig. 1A and Supplementary File 1). Furthermore, GIPC2 mRNA expression was significantly lower in PPGL tumors \((n = 54, \text{one sample showed mRNA degradation which was excluded})\) than normal adrenal medullas \((n = 10)\) (Fig. 1B). The expression level of GIPC2 decreased significantly in copy number deleted tumors compared with copy number normal tumors (Fig. 1C). There was a strong correlation between GIPC2 mRNA expression and gene copy number (Fig. 1D). IHC staining of adrenal tissue sections demonstrated a moderate to high expression of GIPC2 in the nuclei and cytoplasm of normal medulla cells, low expression in tumors without GIPC2 deletion, and no expression of GIPC2 in GIPC2 deletion tumors (Fig. 1E).
Fig. 1 (See legend on next page.)
Western blot also confirmed the significantly reduced GIPC2 protein levels in tumor tissues (Fig. 1F).

We used Sanger sequencing to search for mutations in the six exons and exon/intron border regions of GIPC2. However, we found no germline or somatic mutations of GIPC2 in all 55 PPGL tumors and matched blood samples. Since aberrant promotor methylation was a well-recognized epigenetic mechanism involved in tumor suppressor gene silencing in cancers, we determined the methylation levels of GIPC2 promoter in PPGL samples by MALDI-TOF mass spectrometry (Sequenom EpiTYPER) and found significantly higher levels of methylation in the PPGL samples than normal tissues (Fig. 1G), as well as a negative correlation between GIPC2 mRNA expression and methylation level (Fig. 1H). Methylation-specific PCR of 51 normal and PPGL samples confirmed that reduced GIPC2 expression was associated with promoter hypermethylation (Supplementary Fig. 1C). In PC12 cells, a rat PPGL cell line, the expression of GIPC2 increased 4.9-fold after treatment with DNA methyltransferase inhibitor 5-AZA (Fig. 1I). Similar results were observed in other cell lines (Supplementary Fig. 1D). An examination of a published gene expression database of 188 PPGL samples including 69 hereditary and 119 sporadic tumors (E-MTAB-733) (http://www.ebi.ac.uk/arrayexpress/) found that GIPC2 expression was very low in the cases belonging to Clusters 1A and 2A, but relatively higher in the Cluster 1B and Cluster 2B/2C (Fig. 1J). This reduced expression appeared specific, as it was not observed for another GIPC family member nor for a neighboring gene on the chromosome (PTGFR, whose genome location adjoins GIPC2) (Supplementary Fig. 1E).

Taken together, we have found that a significant fraction of our sporadic PPGLs harbored GIPC2 genomic copy number loss and promoter hypermethylation, correlating with specifically reduced expression of GIPC2 protein.

**GIPC2 suppresses cell proliferation in vitro and in vivo**

GIPC2 protein was normally expressed in the nucleus and the cytoplasm of cultured cells (Fig. 2A). The PDZ domain is important for the nuclear localization of GIPC2 and its cellular stability (Supplementary Fig. 2A–C).

To investigate whether **GIPC2** is a functional tumor suppressor gene, we performed cell proliferation assays, which showed that overexpression of GIPC2 significantly decreased proliferation in PC12 and hPheo1 cells (a cell line derived from a primary human pheochromocytoma), while siGIPC2 significantly increased adrenal chromaffin cells (ACC) proliferation (Fig. 2B). Overexpression of GIPC2 in stably transfected cells inhibited the clone formation (Fig. 2C). The EdU staining assay indicated GIPC2 knockdown increased the cell proliferation in ACC cells (Fig. 2D). However, GIPC2 did not affect cell apoptosis (Supplementary Fig. 2D). Subsequently, a subcutaneous transplantation tumor model in nude BALB/c mice also confirmed the tumor suppression role of GIPC2 in tumor growth in vivo (Fig. 2E, F).

To explore the signaling mechanisms of GIPC2’s growth-inhibitory function, we investigated the MAPK/ERK, PI3K/AKT, and mTOR signaling pathways in GIPC2 overexpressing or knockdown cells. Significant downregulation of phospho-ERK1/2 and phospho-MEK was found in GIPC2 overexpressing cells while the upregulation of them was obtained in GIPC2-knockdown cells (Fig. 2G). However, the levels of phospho-AKT and phospho-mTOR exhibited no obvious changes (Supplementary Fig. 2E). HIF-1A was also upregulated by GIPC2 knockdown and this was independent of the MAPK/ERK pathway, as it was not blocked by MAPK/ERK inhibitor PD98059 (Fig. 2H). The above results indicate that GIPC2 suppresses cell proliferation, tumor growth, and inhibits MAPK/ERK and HIF pathways.
relationship between the expression of GIPC2 and the various cyclin-dependent kinase inhibitors using the data of 188 PPGLs gene expression database (E-MTAB-733). The expression pattern of p27 in the clusters was similar to that of GIPC2 in sporadic PPGL (Fig. 3B). Similar results were obtained in p18 (Supplementary Fig. 3A), but
p16 and p21 did not show such a pattern (Supplementary Fig. 3B). Western blot confirmed that p27 was significantly increased after overexpression of GIPC2 in PC12, 293T, and hPheo1 cells, while decreased when knocking down GIPC2 in HEK293 cells (Fig. 3C). It was reported that p27 protein level is primarily regulated post-translationally through proteasome-mediated degradation

However, we found that GIPC2 did not affect the degradation of p27 (Fig. 3D). These results indicate that GIPC2 transcriptionally regulates p27 to arrest the cell cycle.

**Clinicopathological relevance of GIPC2 and p27 in PPGL**

To examine the clinical significance of the GIPC2-p27 axis in PPGL, we analyzed 182 PPGL cases from the TCGA-PCPG database, which did not distinguish sporadic or hereditary samples (portal.gdc.cancer.gov. Project ID:TCGA-PCPG). The mRNA expression of GIPC2 was positively correlated with p27 (r(spearman) = 0.53) in this cohort (Supplementary Fig. 4A). Kaplan–Meier disease-free survival analysis found that the low expression of both GIPC2 and p27 had a lower disease-free survival time than the relatively high-expression group in PPGL patients (Fig. 3E), providing a clinicopathological relevance of GIPC2–p27 axis in PPGL.

**GIPC2 physically interacts with NONO via PDZ domain**

To further explore the molecular mechanism of tumor suppression by GIPC2, we used immunoprecipitation–mass spectrometry to identify GIPC2 interaction partners. The HA-tagged proteins were enriched by immunoprecipitation and coomassie bright blue staining were used to obtain 4 different bands (Fig. 4A). Mass spectrometry analysis identified 272 putative GIPC2 interacting proteins (Supplementary File 2). A series of nuclear-localized proteins were selected and verified for GIPC2 interaction using fluorescence resonance energy transfer (FRET) assay (Fig. 4B). Among them, NONO (p54nrb), a protein with known functions in regulating transcription

confirmed the interaction of NONO with exogenous or endogenous GIPC2 in vitro (Fig. 4D, E). To investigate the role of PDZ domain in this interaction, glutathione S-transferase (GST) pull-down experiments were performed with bacterially expressed GST fused to GIPC2 or a PDZ domain-deleted mutant. The results revealed that the PDZ domain of GIPC2 was necessary for its interaction with NONO (Fig. 4F). Altogether, these results establish an interaction between GIPC2 and NONO.

**GIPC2 regulates the transcription of p27 through NONO**

Based on the TCGA-PCPG database, the mRNA expression of NONO was positively correlated with p27 (r(spearman) = 0.79) and GIPC2 (r(spearman) = 0.55) (Supplementary Fig. 4A). Knockdown of NONO significantly accelerated cell proliferation in hPheo1 cells (Fig. 4G). Furthermore, overexpression of NONO increased the level of p27, whereas knocking down NONO decreased p27 (Fig. 4H). Thus, NONO can activate the expression of p27 and inhibit cell proliferation, similar to GIPC2.

To evaluate whether NONO was required for the GIPC2 regulation of p27, hPheo1 cells with stable Tet-on GIPC2 (hPheo1-Tet-GIPC2) were transfected with siNONO or siControl, together with or without tetracycline (3 μg/mL) to induce GIPC2. Western blot analysis showed that GIPC2 was no longer able to promote p27 protein level when NONO was knocked down (Fig. 4I). Since GIPC2 had no DNA binding domain, it suggested that GIPC2 regulated the p27 expression via NONO. To verify this, we cloned an 1198 bp fragment (−869/+328) from p27 promoter. Luciferase reporter assay revealed that GIPC2 was able to activate the p27 promoter activity, but not when NONO was knocked down (Fig. 4J). This suggests the critical role of NONO in GIPC2-regulated p27 transcription.

In order to analyze the p27 promoter binding sites for GIPC2/NONO, we established a series of luciferase reporter plasmids for truncated fragments of p27 promoter from −2997, −869, −809, −482, −82, −34, +1,
Luciferase reporter assay revealed that GIPC2 could promote p27 promoter activity by binding to the −34/+1 region of p27 promoter (Supplementary Fig. 5A). Further, we used JASPAR network tool software (http://jaspar.genereg.net/) and PROMO network platform (http://alggen.lsi.upc.es/)
Fig. 4 (See legend on next page.)
The oncogenic effect of RET mutations on chromaffin cells requires the presence of glucocorticoid and is mediated by downregulating GIPC2

While the preceding studies established the tumor-suppressing role of GIPC2 in sporadic PPGLs, we further explored whether GIPC2 had a role in RET mutation-related hereditary PPGL, since all 7 RET-mutated cases in our cohort had GIPC2 loss (Fig. 1A). In the data set of the 188 PPGLs mentioned earlier, GIPC2 and p27 expression were significantly reduced in hereditary RET-related tumors as well (Fig. 5A). We first recapitulated PPGL using primary rat adrenal chromaffin cells (ACC). We demonstrated that in the presence of dexamethasone (Dex), an analog of the adrenal cortical glucocorticoid to which adrenal chromaffin cells are chronically exposed, ACC underwent proliferation instead of differentiation when transfected with either a MEN 2A-causing RET634 mutant or a MEN 2B-causing RET918 mutant (Fig. 5B), while no proliferation or differentiation was observed when ACC was transfected with wild type RET (Fig. 5B) or a FMTC-only RET mutant (RET768, data not shown), consistent with the in vivo MEN2 phenotype. A similar proliferative effect of RET mutant but not wild type can be observed in several cell lines in the presence of Dex (Supplementary Fig. 6A–C). In the absence of Dex, transfection of RET mutant but not wild type RET resulted in apoptosis in ACC (Fig. 5C), and in PC12 when the GIPC2 level was high (Supplementary Fig. 6D). The apoptosis required a specific PDZ domain of GIPC2 (Supplementary Fig. 6E). Treatment of ACC with nerve growth factor (NGF), which induced neuronal differentiation, significantly downregulated GIPC2 (Fig. 5D), while the addition of Dex maintained the chromaffin phenotype (Fig. 5D), induced the expression of GIPC2 and the endocrine cell marker Gα, but downregulated the neuronal marker SCG10 and the accompanying apoptosis (Fig. 5E). These suggest that GIPC2 plays specific roles only in the endocrine but not in neuronal lineage.

The proliferation accelerated in RET634/RET918-transfected cells when GIPC2 was knocked down
Fig. 5B), indicating opposing effects of GIPC2 and PPGL-causing RET mutations on proliferation. We found the level of GIPC2 and p27/p18 downregulated but phospho-ERK1/2 and phospho-RB significantly increased in RET634/RET918-transfected ACCs, while p53 level remained unchanged (Fig. 5F). The downregulation of GIPC2 and p27 expressions were significantly reduced in hereditary NF1-, RET-, SDH-related tumors but not in hereditary VHL-related tumors in the data set of 188 PPGLs from the gene expression database (E-MTAB-733). ACC cells in the presence of 10 μM Dexamethasone (Dex) in the media were transfected with RET634 (p.C634R) or RET918 (p.M918T) mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later. ACC cells were transfected with RET634 mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later. ACC cells were transfected with RET634 mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later. ACC cells were transfected with RET634 mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later. ACC cells were transfected with RET634 mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later. ACC cells were transfected with RET634 mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later. ACC cells were transfected with RET634 mutant plasmid or plasmid with additional GIPC2 knockdown. Cell proliferation was measured with CCK-8 assay at 48 h. ACC cells were transfected with RET WT or RET634 mutant plasmid in the presence or absence of Dex. Apoptosis was assayed using Cell Death Detection ELISA Kit 48 h later.
GIPC2 by RET634 was dose-dependent (Fig. 5G). RET634’s effects on phospho-ERK and on p27 levels, and more importantly on the proliferation phenotype, appeared to be regulated via GIPC2, as these effects can be reversed dose-dependently by increasing GIPC2 (Fig. 5H). Together, these results suggest that the PPGL-causing RET mutation leads to chromafﬁn cell proliferation primarily via downregulating GIPC2.

The oncogenic effect of SDHB mutation on chromafﬁn cells requires the absence of glucocorticoid and is mediated by downregulating GIPC2

We next asked whether GIPC2 had a similar role in mediating the oncogenic effects of SDHx mutations in SDHx-related hereditary PPGL, since SDHx-related hereditary tumors also significantly downregulated GIPC2 and p27 (Fig. 5A). Mutations of the genes encoding succinate dehydrogenase subunits B (SDHB) and D (SDHD) are the most well-known causes of hereditary paraganglia.30 The overexpression of a PPGL-causing SDHB mutation or the knockdown of wild type SDHD protein (both resulted in the increased intracellular concentration of oncometabolite succinate) led to ACC proliferation and corresponding changes of the downstream genes including GIPC2, p27, phosphor-pRb, and phospho-ERK, similar to the RET mutant (Fig. 6A, B). As expected, direct treatment with a cell-permeable succinate analog dimethylsucinate (DMS) also led to ACC proliferation; but contrary to the RET mutant case, the proliferating effect of DMS was abrogated in the presence of Dexamethasone (Fig. 6C). Without Dex, DMS behaved very similarly to the RET634 mutant in the presence of Dex in regulating downstream genes and proliferation phenotype (Figs. 5G, H and 6D, E). Thus, the oncogenic effect of SDHB mutation on chromafﬁn cells requires the absence of glucocorticoid and is mediated by downregulating GIPC2.

Fig. 6 The oncogenic effect of SDHB mutation on chromafﬁn cells requires the absence of glucocorticoid and is mediated by downregulating GIPC2. A The proliferation of ACC cells overexpressing SDHB-mutant (p. R46Q) or si-SDHD was measured at 48 h. B Western blot was performed in ACC cells with SDHB-mutant overexpression or si-SDHD using antibodies against the indicated proteins. C ACC proliferation under 10 mM DMS and/or 10μM Dex treatment. D GIPC2 protein level with increasing DMS concentrations in ACC cells was measured by western blot. E Western blot was performed to measure the protein levels of p27 and phospho-ERK1/2 under 10 mM DMS stimulation and with an increasing amount of GIPC2 plasmid used during transfection of ACC cells. F GIPC2 methylation ratio as measured by EpiTyper assay in ACC transfected with RET and SDHB mutants. G Methylation-specific PCR assay was carried out to detect the methylation of GIPC2 promoter in ACC cells treated with 10 mM DMS and 0.1, 1, and 10 μM Dex.

Official journal of the Cell Death Differentiation Association
effect of PPGL-causing SDHB-mutation is also mediated by downregulating GIPC2.

Previous studies have reported that severe DNA hypermethylation occurred in SDHx-, particularly SDHB-related tumors. We observed drastically increased GIPC2 promoter methylation in chromaffin cells when transfected with SDHB mutant, but not RET mutants (Fig. 6F), suggesting different mechanisms of GIPC2 downregulation by RET- or SDHB-mutation. GIPC2 promoter methylation can also be induced by DMS, but the methylation can be reversed by the presence of the increasing amount of Dex (Fig. 6G). In cell lines, the addition of DMS can also induce GIPC2 methylation as well as proliferation, while in the adrenal they are protected by glucocorticoid to be the environmental factor specifying the tumor location preference. Thus, RET-mutated chromaffin cells in the extra-adrenal (without glucocorticoid) undergo apoptosis and cannot form tumors, while in the adrenal they are protected by glucocorticoid from dying and proliferate (Fig. 5B, C). On the other hand, SDHB-mutated cells proliferate in extra-adrenal to form tumors by virtue of downregulating GIPC2 (Fig. 6), while in the adrenal the proliferation is countered by high expression of GIPC2. Germline mutations of RET and SDHB predispose the carrier to PPGL by downregulating GIPC2. Tumorigenesis begins when a sufficiently-low level of GIPC2 protein is reached, by either additional loss of GIPC2 by LOH of 1p including GIPC2 locus in predisposed cases, or 1p LOH and hypermethylation of GIPC2 locus in sporadic cases. Loss of GIPC2 resulted in p27 repression, activation of HIF-1alpha as well as the pERK pathways, proliferation of chromaffin cells, and possibly with the help of other 1p genes, oncogenic transformations leading to PPGL. We further identified the nucleoprotein NONO as a binding partner of GIPC2 directly regulating p27 transcription. A notable feature of GIPC2 is that it is an endocrine marker (Fig. 5D, E) in the sympathoadrenal lineage and therefore may confer the tissue specificity of the PPGL phenotype. Our model is only for Clusters 1A and 2A tumors and does not exclude the participation of other genes in the oncogenic transformation.

Our study also raises the importance of cortical hormones in PPGL development. Anatomically, the blood flow within the adrenal is directed centripetally from the cortex to the medulla, and the close anatomical cocarcinogenesis of the cortical and chromaffin cells may form the basis for a paracrine interaction. The addition of dexamethasone in chromaffin cell culture media kept the endocrine lineage and made it possible to recapitulate the PPGL phenotype (Fig. 5). It is well-known RET- and SDHx-related PPGLs occur almost exclusively in adrenal or extra-adrenal chromaffin cells, respectively. We find glucocorticoid to be the environmental factor specifying the tumor location preference. Thus, RET-mutated chromaffin cells in the extra-adrenal (without glucocorticoid) undergo apoptosis and cannot form tumors, while in the adrenal they are protected by glucocorticoid from dying and proliferate (Fig. 5B, C). On the other hand, SDHB-mutated cells proliferate in extra-adrenal to form tumors by virtue of downregulating GIPC2 (Fig. 6), while in the adrenal the proliferation is countered by glucocorticoid-induced GIPC2 and tumor seldom forms (Fig. 5). Occasionally, SDHB-related tumors may arise in the adrenal, perhaps when GIPC2 induced by glucocorticoid fails to outweigh SDHx mutation-induced reduction.

Based on GIPC2’s role and expression level, the Cluster 1B (VHL-related) was distinct from Cluster 2A and 1A (RET- and SDHx-related respectively), a classification that was consistent with the cytogenetics observations of large
numbers of PPGLs\textsuperscript{16,17}, which showed the VHL-related tumors with chromosomal deletion patterns (mostly 3pq and 11p) that are distinct from those of RET- and SDHx-related tumors (mostly 1p and 3q). This classification is in contrast to molecular classifications based on expression profiling, which placed VHL-related tumors under “pseudohypoxia” cluster together with SDHx-related tumors\textsuperscript{17,18}. Yet the evidence of a hypoxia mechanism of VHL-associated PPGL is sparse. It is well-known that type 2C VHL mutants, which predispose only to PPGL, are
normal with respect to HIF regulation\textsuperscript{38,39}, suggesting that a VHL target other than HIF is responsible for VHL-associated PPGL. VHL is known to associate with and stabilize p53\textsuperscript{40}. We found the ability of a VHL mutation to predispose to PPGL is reflected by its ability to destabilize p53 and to reduce apoptosis (Fig. 7), suggesting that p53 may be the target mediating the effect of VHL. Given that expression profiling only establishes correlations between pathways and phenotypes, it is possible that the shared “pseudohypoxia” pathways with SDHx cluster may only reflect possible common functional phenotypes (e.g., oxygen sensing, or developmental stage) between the two groups of cells, and may have little to do with the driving mechanism of tumorigenesis.

\textbf{Materials and methods}

\textbf{Patients and samples}

Tumor samples were collected from 55 patients (49 pheochromocytoma and 6 paraganglia) at Peking Union Medical College Hospital, with the clinical information summarized in Supplementary File 1. Normal adrenal medulla tissues from nephrectomy patients were used as normal controls. Samples were collected with approval by the Institute ethics committee and informed consent from the patients.

\textbf{Microarray analysis}

To detect copy number variation (CNV) in sporadic PPGL, Affymetrix genome-wide human SNP array 6.0 was used. The genomic DNA extraction, digestion, PCR, labeling, hybridization, and scanning were performed per the manufacturer’s instructions. Affymetrix HG-U133 plus 2.0 arrays were used to analyze mRNA expression. The total RNA extract, quality control, array hybridization, washing, and scanning were carried out as manufacturer’s instructions. Arrays were scanned and CEL files were imported to Partek Genomics Suite 6.0. The data were normalized using the Robust Multichip Averaging (RMA) algorithm and probe signal intensities were normalized by the MAS5 method.

\textbf{EpiTYPER methylation analysis}

DNA methylation level was quantified with MassARRAY EpiTYPER assays (Sequenom, USA). Primers were designed using EpiDesign (http://www.epidesigner.com). Bisulfite conversion of genomic DNA was

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{fig8.png}
\caption{Proposed model of the molecular mechanism of RET-, SDHx-, and VHL-related hereditary as well as sporadic PPGL.}
\end{figure}
performed using EZ DNA Methylation Kit. The average methylation ratios of the GIPC2 and control groups were calculated as the mean values of the CpG methylation rates and expressed as relative amount of methylation.

**Cell culture and reagents**

PC12, HT-29, HEK293, and 293T cells were obtained from the National Infrastructure of Cell Line Resources, China. The hPheo1-Tet-GIPC2 or PC12-Tet-GIPC2 cells were stable cell lines custom made by Genec copeia, China, and tetracycline or Doxycycline (3 μg/mL) was added to induce overexpression of GIPC2. Primary rat adrenal chromaffin cells were isolated from the adrenal glands according to the protocol of Domínguez et al.41, with the modification that only 5- to 7-days rats were used. All cells were cultured according to the guideline of American type culture collection (ATCC).

The primary antibodies against pERK1/2, ERK1/2, pMEK, MEK, p27, ACTB, p-pRB, p53, HA-Tag were purchased from Cell Signaling Technology (USA), antibodies against NONO, HIF1A, HIF2A, VHL were purchased from Cell Signaling Technology (USA), antibodies against pERK1/2, ERK1/2, and GIPC2-antibodies were purchased from Abcam (UK), antibodies against p18, pRB were purchased from Santa Cruz (USA), GIPC2, and RET antibodies were purchased from LSBio (USA) and Abbiotec (USA) respectively. GIPC2 siRNA were purchased from Dharmacon. SDHD and VHL siRNAs11 were synthesized by Invitrogen. siTran1.0 Reagent (Origene, USA) was used according to the manufacturer’s instructions.

**Tumor formation in nude mice**

For the xenograft model, 4-week-old female BALB/c nude mice were injected subcutaneously with 3 × 10⁶ PC12-Tet-GIPC2 cells. When the volume of tumors reached 80–100 mm³, mice were randomized into 2 groups (n = 8 per group). Group 1 was treated with saline as control, and group 2 was treated with Doxycycline (20 mg/kg) to induce GIPC2 expression by intraperitoneal injection every day. The tumor length (L) and width (W) were measured every 2 days using calipers and then the tumor volume was calculated (tumor volume =0.52 × length × width³). Once the diameter of the tumor exceeded 15 mm, the mice were euthanized. All animal experiments were approved by the animal ethics committee of the Chinese Academy of Medical Sciences.

**Immunoprecipitation-mass spectrometry**

HEK 293T cells were lysed and centrifuged. The supernatants were incubated with primary antibody at 4°C overnight and then captured with protein A+G beads (Beyotime, China) or Ni-NTA beads (GE, USA). The proteins labeled with HA were enriched by immunoprecipitation, and the reaction products were subjected to SDS-PAGE electrophoresis and coomassie blue staining. Different bands in the experimental groups were excised, and in-gel tryptic digested. The digested peptide was analyzed as previously described by LC–MS/MS on a Triple TOF 5600 mass spectrometer (AB Sciex, Framingham, MA, USA). MS/MS data were searched against the SwissProt human database (20227 entries) using Mascot (version 2.4.01; Matrix Science, London, UK), and processed using Scaffold software (version 4.0.7; Proteome Software Inc., Portland, OR, USA).

**Fluorescence resonance energy transfer**

Cells were plated into 8-well culture dishes coated with poly-L-lysine and co-transfected with pairs of expression constructs. After transfection for 48 h, fluorescence signals were collected. All images were acquired using UltraVIEW VoX- 3D Live Cell Imaging System and analyzed using velocity 6.1 software.

**GST pull-down assay**

The constructed plasmids were transformed into BL21 competent cells and a large amount of GST, GIPC2-GST, and GIPC2-△PDZ-GST protein was induced by adding IPTG at room temperature overnight. Then, the proteins were collected after ultrasonic crushing, and mixed with GST-beads (GE, USA), and incubated at 4°C overnight. The mixture was centrifuged, washed, added 293T lysates, and washed again. After discarding the washes, an equal volume of 2× SDS gel-loading buffer was added to the beads. The mixture was boiled for 5 min in a water bath and the supernatants were collected for SDS-PAGE and western blot analysis.

**Dual-luciferase reporter assay**

The wild type, truncated, and mutant p27 promoter were amplified from genomic DNA template using corresponding PCR primers shown in Supplementary Table 3, and cloned into pGL3-basic vector (Promega, USA). After transfection of Reporter and pRL-TK (Renilla) (Promega, USA) or target plasmids for 6 h, the hPheo1-Tet-GIPC2 cells were treated with tetracycline (3 μg/mL) for another 42 h. The cells were then harvested and the luciferase activities measured by the Dual-Luciferase Reporter Assay System (Promega, USA).

**Chromatin immunoprecipitation (ChiP)**

ChiP experiments were performed using Simple ChiP Kit (Cell Signaling Technology, USA). Anti-HA antibody was used to precipitate the DNA–protein complex. Normal IgG provided in Simple ChiP Kit was used as the negative control. Purified DNA obtained from the precipitate was used as the template and PCR was conducted using a pair of primers (Supplementary Table 3), which were designed based on the different NONO-binding sites of the p27 promoter.
Statistical analysis
The data are presented as the mean ± SD of at least three independent experiments. Data were analyzed using the one-way ANOVA method or Student’s t-test, *P < 0.05 was considered statistically significant. GraphPad Prism version 6.00 was used for statistic analysis.

Acknowledgements
We thank Dr. Jenny W. Shay of University of Texas Southwestern Medical Center for providing hPheo1 cells and Dr. Wenji Dong of PUMC for the p53-luciferase reporter plasmid.

Author contributions
Z.Z. designed and supervised the study. Z.G. and D.W. coordinated this study and analyzed the data. Y.D., Y.H., C.F., L.W. and R.Z. conducted the experiments, and W.L. supported some experiments. All authors participated in the draft writing and revising of the final manuscript.

Funding
This work was supported by the CAMS Innovation Fund for Medical Sciences (CIFMS) 2018-2M-1-001, the National Natural Science Foundation of China (No. 31400669), National Key Research and Development Program of China (2016YFC1302203) and the CAMS Special Basic Research Fund for Central Public Research Institutes (No. 2017PT310004).

Data availability
The authors declare that all relevant data of this study are available from the corresponding author on reasonable request.

Conflict of interest
The authors declare no competing interest.

Ethics approval and consent to participate
All clinical samples were collected with informed consent from the patients, and the study of samples was approved by the IRB ethics committees.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03731-7.

Received: 9 October 2020 Revised: 10 April 2021 Accepted: 14 April 2021
Published online: 04 May 2021

References
1. Welander, J., Soderkvist, P. & Gimm, O. Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 18, R253–R276 (2011).
2. Neumann, H. P. H., Young, W. F. Jr. & Eng, C. Pheochromocytoma and paraganglioma. N. Engl. J. Med. 381, 552–65 (2019).
3. Amuedo, V. et al. MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocr. Pathol. 69, 496-503 (2020).
4. Favier, J., Amar, L. & Gimenez-Roqueplo, A. P. Paraganglioma and pheochromocytoma: from genetics to personalized medicine. Nat. Rev. Endocrinol. 11, 101–111 (2015).
5. Castro-Vega, L. J. et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum. Mol. Genet. 23, 2440–2446 (2014).
6. Comino-Mendez, I. et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat. Genet. 43, 663–667 (2011).
7. Bayley, J. et al. SDHAF2 mutations in familial and sporadic paraganglioma and pheochromocytoma. Cancer Oncol. 11, 366–372 (2018).
8. Eisenhofer, G., Klink, B., Richter, S., Lenders, J. W. & Robledo, M. Metabolomics of Pheochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. Clin. Biochem. Rev. 38, 69–100 (2017).
9. Pillai, S., Gopalan, V., Smith, R. A. & Lam, A. K. Updates on the genetics and the clinical impacts on pheochromocytoma and paraganglioma in the new era. Crit. Rev. Oncol. Hematol. 100, 190–206 (2018).
10. Jochmanova, I. & Pacak, K. Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer 4, 6–9 (2018).
11. Lee, S. et al. Neuronal apoptosis linked to EgfR3 p38 hydroxylase and familial pheochromocytoma genes: developmental curing and cancer. Cancer Cell 8, 151–167 (2005).
12. Raue, F. & Frank-Raue, K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones 8, 23–28 (2009).
13. van Veelen, W. et al. P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development. Int. J. Cancer 124, 339–345 (2009).
14. Boren, D. E. et al. Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Res. 60, 7048–7051 (2000).
15. Castro-Vega, L. J., Lepoutre-Lussey, C., Gimenez-Roqueplo, A. P. & Favier, J. Rethinking pheochromocytomas and paragangliomas from a genomic perspective. Oncogene 35, 1080–1089 (2016).
16. Castro-Vega, L. J. et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nat. Commun. 6, 6044 (2015).
17. Fishbein, L. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181–193 (2017).
18. Burnichon, N. et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum. Mol. Genet. 20, 3974–3985 (2011).
19. Besson, A. et al. Discovery of an oncogenic activity in p27kip1 that causes stem cell expansion and a multiple tumor phenotype. Gene Dev. 21, 1731–1746 (2007).
20. Garcia-Fernández, R. A. et al. Combined loss of p21(waf1/cip1) and p27(kip1) enhances tumorigenesis in mice. Lab. Invest. 91, 1634–1642 (2011).
21. Molatore, S. et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol. Cancer 9, 116 (2010).
22. Molatore, S. et al. Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocyto- tama. Proc. Natl. Acad. Sci. USA 107, 18493–18498 (2010).
23. Kikoshi, H. & Katoch, M. Nuclear cloning and characterization of human GIPC2, a novel gene homologous to human GIPC1 and Xenopus kermit. J. Oncol. 20, 571–576 (2002).
24. Katoch, M. Functional proteomics, human genetics and cancer biology of GIPC family members. Exp. Mol. Med. 45, e26 (2013).
25. Kuang, S. Q. et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22, 1529–1538 (2008).
26. Ghayee, H. et al. Progenitor cell line (hPheo1) derived from a human pheochromocytoma tumor. PLoS ONE 8, e66524 (2013).
27. Pagano, M. et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682–685 (1995).
28. Mericq, D. et al. Mutations in NONO lead to syndromic intellectual disability and inhibitory synaptic defects. Nat. Neurosci. 18, 1731–1736 (2015).
29. Pham, D. H. et al. Protocadherin 19 (PDCD19) interacts with paraispeleid protein NONO to co-regulate gene expression with estrogen receptor alpha (ERalpha). Hum. Mol. Genet. 26, 2042–52 (2017).
30. Lee, H. et al. Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers: a systematic review and updated meta-analysis. Journal of medical genetics. J. Med. Genet. 57, 217–225 (2020).
31. Letouze, E. et al. SDH mutations establish a hypermethylation phenotype in paraganglioma. Cancer Cell 23, 739–752 (2013).
32. Chen, F. et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66–75 (1995).
33. Unsicker, K., Krisch, B., Otten, U. & Thoenen, H. Nerve growth factor-induced fiber outgrowth from isolated rat adrenal chromaffin cells: impartment by glucocorticoids. Proc. Natl. Acad. Sci. USA 75, 3498–3502 (1978).

Official journal of the Cell Death Differentiation Association
34. Doupe, A. J., Landis, S. C. & Patterson, P. H. Environmental influences in the development of neural crest derivatives: glucocorticoids, growth factors, and chromaffin cell plasticity. J. Neurosci. 5, 2119–2142 (1985).

35. Anderson, D. J. & Axel, R. A bipotential neuroendocrine precursor whose choice of cell fate is determined by NGF and glucocorticoids. Cell 47, 1079–1090 (1986).

36. Vinson, G. P. & Hinson, J. P. In The Adrenal Gland (ed. James, V.) 71–86 (Raven Press, 1992).

37. Bornstein, S. R., Gonzalez-Hernandez, J. A., Ehrhart-Bornstein, M., Adler, G. & Scherbaum, W. A. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the cellular basis for important intraadrenal interactions. J. Clin. Endocrinol. Metab. 78, 225–232 (1994).

38. Clifford, S. C. et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourogenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029–1038 (2001).

39. Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10, 1019–1027 (2001).

40. Roe, J. S. et al. p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol. Cell 22, 395–405 (2006).

41. Dominguez, N., Rodriguez, M., Machado, J. D. & Borges, R. Preparation and culture of adrenal chromaffin cells. Methods Mol. Biol. 846, 223–234 (2012).

42. Guo, Z., Ching, J., Sun, H. & Sun, W. A qualitative and quantitative evaluation of the peptide characteristics of microwave- and ultrasound-assisted digestion in discovery and targeted proteomic analyses. Rapid Commun. Mass Spectrom. 31, 1353–1362 (2017).